SI2123328T1 - Galantaminski derivati, postopki za njihovo pridobivanje in uporabo - Google Patents
Galantaminski derivati, postopki za njihovo pridobivanje in uporaboInfo
- Publication number
- SI2123328T1 SI2123328T1 SI200930042T SI200930042T SI2123328T1 SI 2123328 T1 SI2123328 T1 SI 2123328T1 SI 200930042 T SI200930042 T SI 200930042T SI 200930042 T SI200930042 T SI 200930042T SI 2123328 T1 SI2123328 T1 SI 2123328T1
- Authority
- SI
- Slovenia
- Prior art keywords
- obtaining
- galanthamine
- methods
- galanthamine derivatives
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BG10110141A BG110141A (en) | 2008-05-23 | 2008-05-23 | GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE |
EP09472001A EP2123328B1 (en) | 2008-05-23 | 2009-02-24 | Galanthamine derivatives, methods for their obtaining and use |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2123328T1 true SI2123328T1 (sl) | 2011-08-31 |
Family
ID=40671399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200930042T SI2123328T1 (sl) | 2008-05-23 | 2009-02-24 | Galantaminski derivati, postopki za njihovo pridobivanje in uporabo |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2123328B1 (sl) |
AT (1) | ATE507881T1 (sl) |
BG (1) | BG110141A (sl) |
DE (1) | DE602009001212D1 (sl) |
PL (1) | PL2123328T3 (sl) |
SI (1) | SI2123328T1 (sl) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8247405B2 (en) * | 2008-12-10 | 2012-08-21 | Conopco, Inc. | Skin lightening compositions with acetylcholinesterase inhibitors |
EP2456434A1 (en) * | 2009-07-23 | 2012-05-30 | Shire LLC | Galantamine amino acid and peptide prodrugs and uses thereof |
BG67337B1 (bg) * | 2018-05-23 | 2021-06-15 | Софарма Ад | Метод за получаване на пречистен галантамин хидробромид |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0944580A2 (en) | 1996-11-22 | 1999-09-29 | Elan Pharmaceuticals, Inc. | N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide release and/or its synthesis |
AR016751A1 (es) | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo |
CZ300160B6 (cs) * | 2000-03-31 | 2009-02-25 | Sanochemia Pharmazeutika Aktiengesellschaft | Deriváty galanthaminu, zpusob výroby techto derivátu, lécivo, které tyto deriváty obsahuje, použitítechto derivátu pro výrobu léciva, zpusob výroby tohoto léciva a zpusob separace (+)- a (-)-izomeruuvedených derivátu |
US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
US20050182044A1 (en) * | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
WO2008022365A2 (de) * | 2006-08-24 | 2008-02-28 | Sanochemia Ltd. | Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel |
-
2008
- 2008-05-23 BG BG10110141A patent/BG110141A/en unknown
-
2009
- 2009-02-24 EP EP09472001A patent/EP2123328B1/en active Active
- 2009-02-24 AT AT09472001T patent/ATE507881T1/de active
- 2009-02-24 DE DE602009001212T patent/DE602009001212D1/de active Active
- 2009-02-24 SI SI200930042T patent/SI2123328T1/sl unknown
- 2009-02-24 PL PL09472001T patent/PL2123328T3/pl unknown
Also Published As
Publication number | Publication date |
---|---|
BG110141A (en) | 2009-12-31 |
PL2123328T3 (pl) | 2011-10-31 |
ATE507881T1 (de) | 2011-05-15 |
EP2123328B1 (en) | 2011-05-04 |
DE602009001212D1 (de) | 2011-06-16 |
EP2123328A1 (en) | 2009-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009008531A (es) | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. | |
TW200716596A (en) | Substituted amide derivatives and methods of use | |
WO2009127642A3 (en) | Use of lrrk2 inhibitors for neurodegenerative diseases | |
TW200734311A (en) | New compounds | |
TNSN06228A1 (en) | Compounds and methods of use | |
MX342477B (es) | Compuestos y su uso como inhibidores de sitio beta de escision de enzima (bace). | |
ZA200709535B (en) | Methods and compositions for the treatment of CNS-related conditions | |
MY167135A (en) | Fused heterocyclic derivatives and methods of use | |
MX2010007683A (es) | Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met. | |
GEP20115172B (en) | Bicyclic cinnamide compound | |
WO2007048070A3 (en) | Pyrrolo-pyridine derivatives for the treatment of cancer diseases | |
WO2007064932A3 (en) | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | |
WO2008086014A3 (en) | Bis-aryl amide derivatives useful for the treatment of cancer | |
EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
MX2010003269A (es) | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. | |
IN2012DN05186A (sl) | ||
WO2010075280A3 (en) | Coumarin-based compounds for the treatment of alzheimer's disease and cancer | |
MY136718A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
IL200029A0 (en) | Methods for the treatment of senile dementia of the alzheimer's type | |
HK1104280A1 (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
ATE402150T1 (de) | Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen | |
SI2123328T1 (sl) | Galantaminski derivati, postopki za njihovo pridobivanje in uporabo | |
WO2009043858A3 (en) | Methods for treating and diagnosing a cancer secreting cath-d or alzheimer's disease | |
ATE473219T1 (de) | Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen | |
MY145068A (en) | Imidazole compounds for the treatment of neurodegenerative disorders |